Home » News » 02/06 » FWyeth Pharmaceuticals forms Irish collaboration

Wyeth Pharmaceuticals forms Irish collaboration

Date published: 14/02/2006

Wyeth Pharmaceuticals has announced a collaboration with Dublin-based Opsona Therapeutics. The partnership will aim to discover and develop compounds to treat inflammatory diseases, based on Toll-like receptor (TLR) targets.

Professor Luke O'Neill, co-founder of Opsona, said: "TLRs are critical initiators of inflammation and have been implicated in the development of chronic inflammatory diseases such as rheumatoid arthritis and systemic lupus erythematosis, in addition to applications in other fields, including cancer and vaccines. "Targeting TLRs with new drug candidates has tremendous potential as a new approach to treat such diseases."

Under the agreement Wyeth will make an upfront payment to Opsona and further payments will be paid on meeting certain discovery and development milestones. Opsona will also take royalties on potential product sales, but no details have been disclosed.

Opsona chairman Dr Cormac Kilty said: "The scientific expertise of Opsona coupled with the capabilities of Wyeth is a great combination for drug discovery and development to bring new drugs into the clinic for the treatment of these disabling diseases. "This collaboration also reaffirms Wyeth's continued investment in the Irish biotechnology sector."

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.